ASH 2023 | Centralized MRD assessment in patients with AML treated with venetoclax + FLAI: GIMEMA AML1718 trial

Paola Minetto, MD, PhD, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, comments on the findings of a centralized measurable residual disease (MRD) assessment at early time points in the Phase II GIMEMA AML1718 trial (NCT03455504), which investigated the safety and efficacy of venetoclax in combination with intensive fludarabine-based induction (FLAI; fludarabine, cytarabine, and idarubicin) in patients with newly diagnosed non-low-risk acute myeloid leukemia (AML). Preliminary results from centralized MRD analysis indicate that this treatment regimen is able to induce high-quality remissions in patients, with a high percentage of multicolor flow cytometry (MFC)-MRD negativity being observed. Dr Minetto also highlights that over half of patients were successfully bridged to allogeneic stem cell transplantation (alloSCT). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.